1. Prior exposure to doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies. 
2. Subjects with platinum-refractory disease, defined as disease progression while receiving first line platinum-based therapy. 
3. Clinically significant persistent immune-related adverse events following prior therapy. 
4. Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage. 
5. Subjects with clinically significant cardiovascular disease. This includes: 
1. Resisted hypertension 
2. Myocardial infarction or unstable angina within 6 months prior to Day 1 of the study. 
3. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication. 
4. Baseline ejection fraction ≤ 50% as assessed by echocardiogram or MUGA. 
5. New York Heart Association (NYHA) Class II or higher congestive heart failure. 
6. Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit. 
6. History of pneumonitis or interstitial lung disease. 
7. Active, suspected or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegner's granulomatosis, active Hashimoto's thyroiditis, rheumatoid arthritis, lupus, scleroderma and its variants, multiple sclerosis, myasthenia gravis). Vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted. 
8. Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only. 
9. Subjects with clinical symptoms or signs of gastrointestinal obstruction and/or who require drainage gastrostomy tube and/or parenteral hydration or nutrition. 
10. Known immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity. 
11. History of severe allergic reactions to any unknown allergens or components of the study drugs. 
12. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders). 
13. Prior treatment in any other interventional clinical trial within 4 weeks prior to Day 1 of the study. 
14. Mental impairment that may compromise compliance with the requirements of the study. 
15. Lack of availability for immunological and clinical follow-up assessment. 
16. Women who are breastfeeding or pregnant as evidenced by positive serum pregnancy test 
17. Subjects unwilling to use acceptable methods of contraception. 
-Female subjects should refrain from breastfeeding throughout this period. 
18. Any condition that, in the clinical judgment of the treating physician, is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk. 
19. Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 treatment. 
20. History of allogeneic organ transplant       
    

NCT02431559_exc_T27
Drug
doxorubicin
NCT02431559_exc_T28
Drug
PLD
NCT02431559_exc_T29
Drug
anthracycline
NCT02431559_exc_T30
Drug
motolimod
NCT02431559_exc_T31
Drug
TLR agonists
NCT02431559_exc_T32
Drug
MEDI4736
NCT02431559_exc_T33
Drug
checkpoint inhibitors
NCT02431559_exc_T34
Drug
anti-CTLA4
NCT02431559_exc_T35
Drug
anti-PD1 antibodies
NCT02431559_exc_T36
Drug
anti-PD-L1 antibodies
NCT02431559_exc_T37
Scope
anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies
NCT02431559_exc_T39
Temporal
Prior
NCT02431559_exc_T40
Scope
doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies
NCT02431559_exc_T41
Condition
platinum-refractory disease
NCT02431559_exc_T43
Condition
disease progression
NCT02431559_exc_T44
Temporal
while receiving first line platinum-based therapy
NCT02431559_exc_T45
Reference_point
first line platinum-based therapy
NCT02431559_exc_T46
Condition
immune-related adverse events
NCT02431559_exc_T47
Temporal
following prior therapy
NCT02431559_exc_T48
Reference_point
prior therapy
NCT02431559_exc_T49
Qualifier
Clinically significant
NCT02431559_exc_T50
Qualifier
persistent
NCT02431559_exc_T53
Condition
CNS disease
NCT02431559_exc_T54
Condition
primary brain tumor
NCT02431559_exc_T55
Condition
seizures
NCT02431559_exc_T56
Qualifier
controlled
NCT02431559_exc_T57
Negation
not
NCT02431559_exc_T58
Drug
standard medical therapy
NCT02431559_exc_T59
Condition
brain metastases
NCT02431559_exc_T60
Temporal
within six months prior to Day 1 of this study
NCT02431559_exc_T61
Reference_point
Day 1 of this study
NCT02431559_exc_T62
Condition
cerebrovascular accident
NCT02431559_exc_T63
Condition
CVA
NCT02431559_exc_T64
Condition
stroke
NCT02431559_exc_T65
Scope
CVA, stroke
NCT02431559_exc_T66
Condition
transient ischemic attack (TIA)
NCT02431559_exc_T67
Condition
subarachnoid hemorrhage
NCT02431559_exc_T68
Scope
cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage
NCT02431559_exc_T69
Condition
cardiovascular disease
NCT02431559_exc_T70
Qualifier
clinically significant
NCT02431559_exc_T74
Condition
Resisted hypertension
NCT02431559_exc_T75
Condition
Myocardial infarction
NCT02431559_exc_T76
Condition
unstable angina
NCT02431559_exc_T77
Temporal
within 6 months prior to Day 1 of the study
NCT02431559_exc_T78
Reference_point
Day 1 of the study
NCT02431559_exc_T79
Condition
ventricular arrhythmia
NCT02431559_exc_T80
Scope
Myocardial infarction or unstable angina
NCT02431559_exc_T81
Condition
ventricular tachycardia
NCT02431559_exc_T82
Condition
ventricular fibrillation
NCT02431559_exc_T83
Scope
ventricular tachycardia or ventricular fibrillation
NCT02431559_exc_T84
Qualifier
serious
NCT02431559_exc_T85
Observation
History
NCT02431559_exc_T86
Condition
cardiac arrhythmias
NCT02431559_exc_T87
Drug
anti-arrhythmic medications
NCT02431559_exc_T88
Qualifier
requiring anti-arrhythmic medications
NCT02431559_exc_T89
Condition
atrial fibrillation
NCT02431559_exc_T90
Negation
except
NCT02431559_exc_T91
Qualifier
well controlled with anti-arrhythmic medication
NCT02431559_exc_T92
Drug
anti-arrhythmic medication
NCT02431559_exc_T93
Measurement
ejection fraction
NCT02431559_exc_T94
Temporal
Baseline
NCT02431559_exc_T95
Value
≤ 50%
NCT02431559_exc_T96
Procedure
echocardiogram
NCT02431559_exc_T97
Procedure
MUGA
NCT02431559_exc_T98
Scope
echocardiogram or MUGA
NCT02431559_exc_T99
Measurement
New York Heart Association (NYHA)
NCT02431559_exc_T100
Value
Class II or higher
NCT02431559_exc_T101
Condition
congestive heart failure
NCT02431559_exc_T102
Condition
peripheral ischemia
NCT02431559_exc_T103
Qualifier
Grade 2 or higher
NCT02431559_exc_T104
Value
2 or higher
NCT02431559_exc_T105
Temporal
brief
NCT02431559_exc_T106
Value
< 24 hrs
NCT02431559_exc_T107
Condition
ischemia
NCT02431559_exc_T108
Procedure
surgically
NCT02431559_exc_T109
Negation
non
NCT02431559_exc_T110
Condition
permanent deficit
NCT02431559_exc_T111
Negation
without
NCT02431559_exc_T112
Negation
except
NCT02431559_exc_T113
Scope
brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit
NCT02431559_exc_T114
Condition
pneumonitis
NCT02431559_exc_T115
Condition
interstitial lung disease
NCT02431559_exc_T116
Observation
History
NCT02431559_exc_T117
Condition
autoimmune disease
NCT02431559_exc_T118
Condition
inflammatory bowel disease
NCT02431559_exc_T119
Condition
celiac disease
NCT02431559_exc_T120
Condition
Wegner's granulomatosis
NCT02431559_exc_T121
Condition
Hashimoto's thyroiditis
NCT02431559_exc_T122
Condition
rheumatoid arthritis
NCT02431559_exc_T123
Condition
lupus
NCT02431559_exc_T124
Condition
scleroderma
NCT02431559_exc_T125
Condition
scleroderma variants
NCT02431559_exc_T126
Condition
multiple sclerosis
NCT02431559_exc_T127
Condition
myasthenia gravis
NCT02431559_exc_T128
Scope
inflammatory bowel disease, celiac disease, Wegner's granulomatosis, active Hashimoto's thyroiditis, rheumatoid arthritis, lupus, scleroderma and its variants, multiple sclerosis, myasthenia gravis
NCT02431559_exc_T129
Condition
Vitiligo
NCT02431559_exc_T130
Condition
type I diabetes mellitus
NCT02431559_exc_T131
Condition
residual hypothyroidism
NCT02431559_exc_T132
Condition
autoimmune condition
NCT02431559_exc_T133
Qualifier
due to autoimmune condition
NCT02431559_exc_T134
Drug
hormone replacement
NCT02431559_exc_T135
Qualifier
requiring hormone replacement
NCT02431559_exc_T136
Qualifier
requiring systemic treatment
NCT02431559_exc_T137
Procedure
systemic treatment
NCT02431559_exc_T138
Negation
not
NCT02431559_exc_T139
Condition
psoriasis
NCT02431559_exc_T140
Qualifier
not expected to recur
NCT02431559_exc_T142
Condition
conditions
NCT02431559_exc_T144
Temporal
within 2 years prior to Day 1 of the study
NCT02431559_exc_T145
Reference_point
Day 1 of the study
NCT02431559_exc_T146
Condition
malignancy
NCT02431559_exc_T147
Procedure
surgical intervention
NCT02431559_exc_T148
Negation
except for
NCT02431559_exc_T149
Condition
those
NCT02431559_exc_T151
Condition
clinical symptoms of gastrointestinal obstruction
NCT02431559_exc_T152
Condition
signs of gastrointestinal obstruction
NCT02431559_exc_T153
Device
drainage gastrostomy tube
NCT02431559_exc_T154
Procedure
parenteral hydration
NCT02431559_exc_T155
Procedure
parenteral nutrition
NCT02431559_exc_T156
Condition
immunodeficiency
NCT02431559_exc_T157
Condition
HIV
NCT02431559_exc_T158
Condition
Hepatitis B
NCT02431559_exc_T159
Condition
Hepatitis C
NCT02431559_exc_T160
Condition
allergic reactions
NCT02431559_exc_T161
Qualifier
severe
NCT02431559_exc_T162
Observation
History
NCT02431559_exc_T164
Drug
to any unknown allergens or components of the study drugs
NCT02431559_exc_T163
Condition
illnesses
NCT02431559_exc_T166
Qualifier
serious
NCT02431559_exc_T169
Condition
infections requiring antibiotics
NCT02431559_exc_T171
Qualifier
serious
NCT02431559_exc_T172
Condition
bleeding disorders
NCT02431559_exc_T173
Scope
serious infections requiring antibiotics, bleeding disorders
NCT02431559_exc_T174
Procedure
treatment
NCT02431559_exc_T177
Condition
Mental impairment
NCT02431559_exc_T178
Observation
compromise compliance
NCT02431559_exc_T182
Observation
breastfeeding
NCT02431559_exc_T183
Condition
pregnant
NCT02431559_exc_T184
Person
Women
NCT02431559_exc_T185
Measurement
serum pregnancy test
NCT02431559_exc_T186
Value
positive
NCT02431559_exc_T187
Scope
breastfeeding or pregnant
NCT02431559_exc_T190
Person
Female
NCT02431559_exc_T191
Observation
breastfeeding
NCT02431559_exc_T193
Temporal
throughout this period.
NCT02431559_exc_T194
Reference_point
this period
NCT02431559_exc_T199
Procedure
donate blood
NCT02431559_exc_T200
Negation
not
NCT02431559_exc_T201
Temporal
while on study
NCT02431559_exc_T202
Reference_point
on study
NCT02431559_exc_T203
Temporal
for at least 90 days following the last MEDI4736 treatment
NCT02431559_exc_T204
Reference_point
the last MEDI4736 treatment
NCT02431559_exc_T205
Scope
while on study and for at least 90 days following the last MEDI4736 treatment
NCT02431559_exc_T206
Procedure
allogeneic organ transplant
NCT02431559_exc_T207
Observation
History
NCT02431559_exc_T176
Temporal
Prior
NCT02431559_exc_T188
Negation
refrain from
NCT02431559_exc_T180
Negation
Lack of
NCT02431559_exc_T181
Procedure
immunological follow-up assessment
NCT02431559_exc_T189
Procedure
clinical follow-up assessment
NCT02431559_exc_T192
Scope
immunological and clinical follow-up assessment
NCT02431559_exc_T195
Mood
availability for
NCT02431559_exc_T196
Condition
unwilling
NCT02431559_exc_T208
Qualifier
acceptable
NCT02431559_exc_T209
Procedure
contraception